A purified polypeptide includes an NADPH oxidase cytosolic cofactor polypeptide NOXA1 or P67phox having a C-terminal SH3 domain insertion mutation of at least three consecutive amino acids positioned between PEDL and GIFPK motifs of said SH3 domain so as to reduce activity of the purified polypeptide relative to the wild-type cofactor polypeptide. A process for treating, inhibiting, or prophylatically preventing a disease associated with the overproduction of reactive oxygen species involving NOXn where n is 1-4 inclusive includes the administration of a therapeutically effective amount with a purified polypeptide to a subject tissue that is overproducing reactive oxygen species through a NOXn pathway.
展开▼